DACLATASVIR dihydrochl. eq.60mg base/ SOFOSBUVIR 400mg, tab.
STD
DORADASO64T
Valid Article
HS Code:
300490
Last Updated on:
22/10/2024, 12:18:51
6.4.4.2.1 - Pangenotypic direct-acting antiviral combinations
Classification of the medicines in groups and subgroups according to their therapeutic use.
The classification used by MSF is based on the WHO Model List of Essential Medicines.
J05AP07
Anatomical Therapeutic Chemical Classification according to WHOCC
OC subscriptions: included in supply or field order tools (e.g. UniField)
|
|
SC subscriptions: included in supply or field tools
|
|
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)
|
|
DACLATASVIR/ SOFOSBUVIR (DCV/SOF)
Therapeutic Action
Fixed dose combination of a NS5A inhibitor (daclatasvir) and a nucleotide analogue NS5B polymerase inhibitor (sofosbuvir)
Indications
Chronic hepatitis C virus (HCV)
Some restricted information has been hidden. Sign in
to see this information
Instructions for use
Tablets have a bitter taste, they should be swallowed whole (not crushed or chewed), with meals.
The FDC replaces the single tablets of 60 mg daclastavir and 400 mg sofosbuvir.
To be used in combination with or without ribavirin.
Storage
Below 25ºC